LNC Therapeutics, a French company specializing in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, raised €6.5 million ($7.7 million) in Series C funding.
In the same category
Press / Medias
LNC Therapeutics selected by BNP Paribas for its innovative approach to beat obesity